News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
707,798 Results
Type
Article (41926)
Company Profile (331)
Press Release (665541)
Section
Business (210170)
Career Advice (2082)
Deals (36583)
Drug Delivery (100)
Drug Development (82857)
Employer Resources (171)
FDA (16493)
Job Trends (15363)
News (355501)
Policy (33832)
Tag
Academia (2574)
Alliances (51190)
Alzheimer's disease (1282)
Approvals (16458)
Artificial intelligence (159)
Bankruptcy (364)
Best Places to Work (11716)
Biotechnology (213)
Breast cancer (193)
Cancer (1416)
Cardiovascular disease (116)
Career advice (1742)
Cell therapy (289)
Clinical research (66268)
Collaboration (502)
Compensation (274)
COVID-19 (2613)
C-suite (111)
Data (1407)
Diabetes (180)
Diagnostics (6256)
Earnings (86593)
Employer resources (149)
Events (112926)
Executive appointments (412)
FDA (17204)
Funding (447)
Gene therapy (210)
GLP-1 (634)
Government (4453)
Healthcare (18891)
Infectious disease (2706)
Inflammatory bowel disease (115)
Interviews (320)
IPO (16631)
Job creations (4052)
Job search strategy (1488)
Layoffs (441)
Legal (8329)
Lung cancer (203)
Lymphoma (101)
Manufacturing (216)
Medical device (13300)
Medtech (13305)
Mergers & acquisitions (20130)
Metabolic disorders (480)
Neuroscience (1617)
NextGen Class of 2024 (6624)
Non-profit (4515)
Northern California (1730)
Obesity (273)
Opinion (208)
Patents (125)
People (58436)
Phase I (20527)
Phase II (29155)
Phase III (21867)
Pipeline (518)
Postmarket research (2651)
Preclinical (8730)
Radiopharmaceuticals (241)
Rare diseases (277)
Real estate (6241)
Regulatory (22543)
Research institute (2359)
Resumes & cover letters (358)
Southern California (1485)
Startups (3712)
United States (15575)
Vaccines (583)
Weight loss (198)
Date
Last 7 days (171)
Last 30 days (1619)
Last 365 days (35061)
2025 (91)
2024 (35807)
2023 (40631)
2022 (51797)
2021 (56329)
2020 (54794)
2019 (47400)
2018 (35771)
2017 (33137)
2016 (32662)
2015 (38615)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (776)
Arizona (203)
Asia (40173)
Australia (6427)
California (3899)
Canada (1480)
China (330)
Colorado (176)
Connecticut (183)
Europe (85509)
Florida (550)
Georgia (136)
Illinois (399)
Indiana (235)
Maryland (647)
Massachusetts (3044)
Michigan (177)
Minnesota (297)
New Jersey (1139)
New York (1110)
North Carolina (764)
Northern California (1730)
Ohio (148)
Pennsylvania (946)
South America (1158)
Southern California (1485)
Texas (570)
Utah (109)
Washington State (410)
707,798 Results for "tracon pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the first quarter ended March 31, 2024.
May 14, 2024
·
9 min read
Deals
TRACON Pharmaceuticals Announces Reverse Stock Split - April 8, 2024
TRACON Pharmaceuticals today announced that, following stockholder approval at the special meeting of stockholders held on September 6, 2023 of a proposal authorizing the board of directors of the Company.
April 8, 2024
·
4 min read
TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform
TRACON Pharmaceuticals (NASDAQ: TCON) today announced the objective response rate (ORR) by blinded independent central review (BICR) in the fully enrolled ENVASARC pivotal trial in the 82 evaluable patients is 5% (four responders), which is lower than the primary endpoint of the study of 11% ORR by BICR needed to support a biologics license application (BLA).
July 1, 2024
·
5 min read
Business
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
TRACON Pharmaceuticals, Inc. (Nasdaq: TCON) today announced financial results for the fourth quarter and year ended December 31, 2023.
March 5, 2024
·
9 min read
Business
TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
TRACON Pharmaceuticals, Inc. announced that it will report its first quarter 2024 financial and operating results after the close of U.S. financial markets on Tuesday, May 14, 2024.
May 7, 2024
·
2 min read
Business
TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
TRACON Pharmaceuticals, Inc. announced financial results for the third quarter ended September 30, 2023.
November 9, 2023
·
10 min read
Drug Development
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned
TRACON Pharmaceuticals (NASDAQ: TCON) today announced the independent data monitoring committee (IDMC), following a review of ongoing safety and efficacy data on April 2, recommended the ENVASARC Phase 2 pivotal trial continue as planned.
April 3, 2024
·
4 min read
Business
TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024
TRACON Pharmaceuticals, Inc. announced that it will report its fourth quarter and year-end 2023 financial and operating results after the close of U.S. financial markets on Tuesday, March 5, 2024.
February 28, 2024
·
2 min read
Biotech Beach
TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment
TRACON Pharmaceuticals, Inc. announced it has licensed its proprietary PDP of CRO-independent clinical research to a clinical stage biotech company for a $3.0 million upfront payment.
November 20, 2023
·
4 min read
Drug Development
TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients
TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent Product Development Platform (PDP) to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced the publication of Phase 2 clinical data of its DNA damage repair inhibitor drug candidate, TRC102, in patients with glioblastoma in Clinical Cancer Research.
June 11, 2024
·
7 min read
1 of 70,780
Next
